Avidity Biosciences Inc (RNA NASDAQ) stock market data APIs
$28.79
1.74(6.4%)
as of January 14, 2025
Avidity Biosciences Inc Financial Data Overview
Price chart is built with
Anychart
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
Prev. Close
27.05
Open
28.79
Volume
1 701 K
High
29.035
Low
26.74
52 wk Range
9.93-56
Market Cap
3 227 M
Shares Outstanding
119 M
Revenue
10 117 K
EPS
-0.65
Beta
0.908
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Avidity Biosciences Inc data using free add-ons & libraries
Get Avidity Biosciences Inc Fundamental Data
Avidity Biosciences Inc Fundamental data includes:
- Net Revenue: 10 117 K
- EBITDA: -322 036 000
- Earnings Per Share: -2
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2024-11-06
- EPS/Forecast: -0.71
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Avidity Biosciences Inc News
New
Avidity Biosciences Announces FDA Removed Partial Clinical Hold on Delpacibart Etedesiran (del-desiran/AOC 1001)
SAN DIEGO, Oct. 3, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Con...
Is Avidity Biosciences, Inc. (RNA) the Best Performing Long Term Stock in 2024?
We recently published a list of the 7 Best Performing Long Term Stocks in 2024. In this article, we are going to take a look at where Avidity Biosciences, Inc. (NASDAQ:RNA) stands against the other be...
Is Avidity Biosciences Inc. (RNA) the Best Performing Small-Cap Stock in 2024?
We recently compiled a list of the 10 Best Performing Small-Cap Stocks in 2024. In this article, we will look at where Avidity Biosciences Inc. (NASDAQ:RNA) ranks among the best-performing small-cap s...
Avidity Biosciences to Participate in Upcoming Investor Conference
SAN DIEGO, Sept. 25, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide C...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
